The human amniotic membrane is the innermost layer of the placenta that protects the developing fetus, playing a vital role during pregnancy. Research confirms this biologically rich tissue holds remarkable therapeutic potential well beyond gestation. Packed with collagen, antimicrobial peptides, anti-inflammatory cytokines and essential growth factors such as EGF and TGF-β, the membrane actively supports epithelial healing, calms inflammation and delivers measurable improvements in wound care and ocular surface repair. Axolotl Biologix is at the forefront of translating this scientific promise into clinical impact. By developing targeted biologic therapies derived from amniotic tissue, it is redefining how complex wounds and soft tissue injuries are treated. What was once discarded as medical waste is now being transformed into a powerful tool for regenerative healing. Its flagship allografts, Axolotl Graft^™ and Axolotl DualGraft^™, embody this innovative solution. Purpose-built to leverage the natural regenerative properties of the human amniotic membrane, the advanced biologics create a three-dimensional, extracellular matrix that covers and shields the wound, reinforces structural support and delivers key biological cues that accelerate granulation tissue formation and encourage scar-minimizing regeneration. “Our mission is to activate the body’s intrinsic repair mechanisms and improve the likelihood of functional recovery, especially where traditional interventions have failed,” says Josh Sandberg, CEO. Physician insights inform every stage of product development, from the most common wound dimensions to the anatomical barriers that challenge conventional approaches. Feedback drives ongoing refinement, ensuring each outcome aligns with evolving standards of care and addresses real-world wound-healing needs..

A young boy’s sixth birthday was approaching, the day that he would become ineligible to receive a newly approved therapy for a rare genetic condition. Missing that deadline would have meant losing access to treatment. When his case reached Orsini, the team acted immediately, coordinating with the prescriber, family, payor, and manufacturer. Approvals were secured in record time, and the therapy was dispensed the day before his birthday, making him one of the first commercial patients in the U.S. to receive it. For Orsini, moments like these define the company’s purpose: speed, precision, and compassion when it matters most. Founded in 1987, Orsini has grown in recent years into a critical partner across the cell and gene therapy (CGT) ecosystem. The company’s approach is rooted in collaboration with patients, providers, biopharmaceutical innovators, and payors who share a common goal: to ensure that life-changing therapies reach the people who need them. At the heart of every process lies Orsini’s enduring promise: No Patient Left Behind. Every patient story at Orsini is personal. Blending precision with empathy, the company has guided over 6,800 patients and countless families, providers, and biopharma partners through the intricate pathways of cell and gene therapy, ensuring that care is as compassionate as it is exacting. Orsini provides the operational backbone for biopharmaceutical partners, turning therapy launches into coordinated successes. It delivers a streamlined pathway for healthcare providers by aiding with the benefit verification, reimbursement, and patient education processes. And for patients and families, it offers a steady hand—someone who understands that behind every form, signature, and vial is a life waiting for change..